 Neoplasms
"Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Descriptor ID |
D009369
|
| MeSH Number(s) |
C04
|
| Concept/Terms |
Neoplasms- Neoplasms
- Neoplasia
- Neoplasias
- Neoplasm
- Tumors
- Tumor
Cancer- Cancer
- Cancers
- Malignant Neoplasms
- Malignant Neoplasm
- Neoplasm, Malignant
- Neoplasms, Malignant
- Malignancy
- Malignancies
Benign Neoplasms- Benign Neoplasms
- Neoplasms, Benign
- Benign Neoplasm
- Neoplasm, Benign
|
Below are MeSH descriptors whose meaning is more general than "Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Neoplasms".
This graph shows the total number of publications written about "Neoplasms" by people in this website by year, and whether "Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 3 | 2 | 5 | | 1994 | 11 | 3 | 14 | | 1995 | 8 | 5 | 13 | | 1996 | 9 | 5 | 14 | | 1997 | 8 | 1 | 9 | | 1998 | 16 | 3 | 19 | | 1999 | 7 | 3 | 10 | | 2000 | 7 | 5 | 12 | | 2001 | 16 | 7 | 23 | | 2002 | 15 | 6 | 21 | | 2003 | 21 | 0 | 21 | | 2004 | 19 | 6 | 25 | | 2005 | 21 | 10 | 31 | | 2006 | 37 | 11 | 48 | | 2007 | 40 | 9 | 49 | | 2008 | 57 | 17 | 74 | | 2009 | 59 | 16 | 75 | | 2010 | 49 | 9 | 58 | | 2011 | 62 | 11 | 73 | | 2012 | 45 | 9 | 54 | | 2013 | 53 | 15 | 68 | | 2014 | 76 | 13 | 89 | | 2015 | 76 | 14 | 90 | | 2016 | 78 | 15 | 93 | | 2017 | 72 | 18 | 90 | | 2018 | 77 | 11 | 88 | | 2019 | 90 | 18 | 108 | | 2020 | 103 | 12 | 115 | | 2021 | 99 | 9 | 108 | | 2022 | 74 | 1 | 75 |
To return to the timeline, click here.
Below are the most recent publications written about "Neoplasms" by people in Profiles.
-
Andrysik Z, Sullivan KD, Kieft JS, Espinosa JM. PPM1D suppresses p53-dependent transactivation and cell death by inhibiting the Integrated Stress Response. Nat Commun. 2022 12 01; 13(1):7400.
-
Torphy RJ, Yee EJ, Schulick RD, Zhu Y. Atypical chemokine receptors: emerging therapeutic targets in cancer. Trends Pharmacol Sci. 2022 12; 43(12):1085-1097.
-
Parikh RB, Basen-Enquist KM, Bradley C, Estrin D, Levy M, Lichtenfeld JL, Malin B, McGraw D, Meropol NJ, Oyer RA, Sheldon LK, Shulman LN. Digital Health Applications in Oncology: An Opportunity to Seize. J Natl Cancer Inst. 2022 10 06; 114(10):1338-1339.
-
Hsieh EM, Myers RM, Yates B, Annesley C, John S, Taraseviciute A, Steinberg SM, Sheppard J, Chung P, Chen L, Lee DW, DiNofia A, Grupp SA, Verneris MR, Laetsch TW, Bhojwani D, Brown PA, Pulsipher MA, Rheingold SR, Gardner RA, Gore L, Shah NN, Lamble AJ. Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy. Blood Adv. 2022 09 13; 6(17):5222-5226.
-
Kim TW, Burris HA, de Miguel Luken MJ, Pishvaian MJ, Bang YJ, Gordon M, Awada A, Camidge DR, Hodi FS, McArthur GA, Miller WH, Cervantes A, Chow LQ, Lesokhin AM, Rutten A, Sznol M, Rishipathak D, Chen SC, Stefanich E, Pourmohamad T, Anderson M, Kim J, Huseni M, Rhee I, Siu LL. First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors. Clin Cancer Res. 2022 08 15; 28(16):3452-3463.
-
Bradley CJ, Kitchen S, Bhatia S, Bynum J, Darien G, Lichtenfeld JL, Oyer R, Shulman LN, Sheldon LK. Policies and Practices to Address Cancer's Long-Term Adverse Consequences. J Natl Cancer Inst. 2022 08 08; 114(8):1065-1071.
-
Seal S, Ghosh D. MIAMI: mutual information-based analysis of multiplex imaging data. Bioinformatics. 2022 08 02; 38(15):3818-3826.
-
Doke K, Chen AM. Rare Tumor, Common Approach. Int J Radiat Oncol Biol Phys. 2022 08 01; 113(5):913.
-
Boland PM, Fountzilas C, Fakih M, Opyrchal M, Diamond JR, Corr B, Ma WW, Redman M, Chan WK, Wang H, Kramer D, Kwan R, Cutler D, Zhi J, Jimeno A. A dose regimen-finding study to evaluate the safety, tolerability, pharmacokinetics, and activity of oratecan in subjects with advanced malignancies. Cancer Chemother Pharmacol. 2022 08; 90(2):175-187.
-
Marker RJ, Ostendorf DM, Leach HJ, Peters JC. Cancer-related fatigue mediates the relationships between physical fitness and attendance and quality of life after participation in a clinical exercise program for survivors of cancer. Qual Life Res. 2022 Nov; 31(11):3201-3210.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|